Marshall Wace, LLP Kymera Therapeutics, Inc. Transaction History
Marshall Wace, LLP
- $90.8 Billion
- Q3 2025
A detailed history of Marshall Wace, LLP transactions in Kymera Therapeutics, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 359,076 shares of KYMR stock, worth $23.3 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
359,076
Previous 269,284
33.34%
Holding current value
$23.3 Million
Previous $11.8 Million
72.95%
% of portfolio
0.02%
Previous 0.01%
Shares
11 transactions
Others Institutions Holding KYMR
# of Institutions
222Shares Held
73.9MCall Options Held
144KPut Options Held
58.1K-
Baker Bros. Advisors LP New York, NY6.65MShares$432 Million3.07% of portfolio
-
Avoro Capital Advisors LLC New York, NY6.35MShares$412 Million4.91% of portfolio
-
Bvf Inc San Francisco, CA5.5MShares$357 Million16.85% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.42MShares$352 Million0.0% of portfolio
-
Wellington Management Group LLP Boston, MA5.2MShares$337 Million0.05% of portfolio
About Kymera Therapeutics, Inc.
- Ticker KYMR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 54,705,800
- Market Cap $3.55B
- Description
- Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...